Evidence map›Paper›PMID 41619789›Full record

ReviewNeuro-oncology2026

A brief history of ependymoma.

David R Ghasemi, Denise Obrecht-Sturm, Kimberly M Wallgren, Martin U Schuhmann, Beate Timmermann, Stefan Rutkowski, Ulrich Schüller, Kristian W Pajtler

Abstract readReviewHistorical Article
In one paragraph

Review in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

David R GhasemiDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-3844-9933
Denise Obrecht-SturmDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-3216-8452
Kimberly M WallgrenCollaborative Ependymoma Research Network (CERN), A Program of the National Brain Tumor Society, Newton, Massachusetts, USA (K.M.W.).
Martin U SchuhmannSection of Pediatric Neurosurgery, Department of Neurosurgery, University Hospital Tuebingen, Tuebingen, -Germany (M.U.S.).
Beate TimmermannDepartment of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Essen, Germany.
Stefan RutkowskiDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-5446-9571
Ulrich SchüllerDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-8731-1121
Kristian W PajtlerHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-3562-6121

Funding

Clinician Scientist program Mildred Scheel Cancer Career Center HaTriCS4 at the University Medical Center Hamburg-Eppendorf, funded by the German Cancer AidDeutsche Forschungsgemeinschaft and the Fördergemeinschaft Kinderkrebszentrum HamburgElse Kröner-Fresenius StiftungFight Kids Cancer (FKC)German Children's Cancer Foundation
6 · The paper itself

Abstract

Ependymoma represents a biologically and clinically heterogeneous group of glial tumors that arise throughout the whole neuroaxis and in all age groups. Whereas intracranial ependymoma is usually found in children, adults suffer mostly from spinal cord ependymoma. In comparison to other neuro-oncological tumor entities, ependymoma has been largely understudied for decades. However, the recent years resulted in unprecedented progress with regard to the understanding of the biological underpinnings and clinical features of ependymoma. Here, we review the history of ependymoma research with a focus on the development of classification models throughout the years and a discussion of the most important clinical trials that have led to the current therapeutic standard, comprising maximal safe resection and, in most cases, radiotherapy. Critically, the evidence for effective drugs and chemotherapies in ependymoma is still sparse. However, these important questions may be soon addressed with the finalization of the currently unpublished last generation of multi-institutional trials in Europe (SIOP EP II) and Northern America (ACNS0831). Lastly, we discuss the current challenges in the field of ependymoma research and the necessary next steps toward the goal of findings cures for all types of ependymal tumors.

Indexed as

Brain NeoplasmsEpendymomaHistory, 20th CenturyHistory, 21st CenturyHumansependymal tumorsependymomamedical historymolecular classification

Identifiers

PMID41619789
PMCPMC13186465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.